Title:
PHARMACEUTICAL COMPOSITION COMPRISING HUMAN HYALURONIDASE PH20 AND DRUG
Document Type and Number:
WIPO Patent Application WO/2023/075506
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition comprising (a) a drug, (b) PH20 or a variant thereof, and (c) a poloxamer-based surfactant. The human PH20 variant contained in the pharmaceutical composition according to the present invention includes an amino acid substitution at one or more positions selected from the alpha helix 8 sequence (S347-C381) and a linkage region (A333-R346) between alpha helix 7 and alpha helix 8 on the wild-type human pH20 having the amino acid sequence of SEQ IS NO: 1, and is optionally cleaved at an amino acid positioned at the N-terminal and/or C-terminal region. In addition, the pharmaceutical composition according to the present invention may further comprise a pharmaceutically acceptable additive, particularly, a stabilizer. Due to the advantage of the human PH20 or the variant thereof, the pharmaceutical composition according to the present invention can exhibit a maximum therapeutic effect of the drug used together therewith.
Inventors:
PARK SOON JAE (KR)
KIM KYUWAN (KR)
NAM KI SEOK (KR)
SONG HYUNG-NAM (KR)
KIM KYUWAN (KR)
NAM KI SEOK (KR)
SONG HYUNG-NAM (KR)
Application Number:
PCT/KR2022/016709
Publication Date:
May 04, 2023
Filing Date:
October 28, 2022
Export Citation:
Assignee:
ALTEOGEN INC (KR)
International Classes:
A61K9/00; A61K39/00; A61K47/10; A61K47/42; C12N9/26
Domestic Patent References:
| WO2013102144A2 | 2013-07-04 |
Foreign References:
| KR101874401B1 | 2018-07-04 | |||
| KR20200130451A | 2020-11-18 | |||
| KR20120105426A | 2012-09-25 | |||
| KR20200017538A | 2020-02-18 |
Attorney, Agent or Firm:
LEE, Cheo Young et al. (KR)
Download PDF: